GlassScriptPhysician profile
Richard E Rainville
NPI 1023507290
$1,967.80
in general payments reported to CMS, 2019-2025
22 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.29 · 2023: $146 · 2024: $216 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.51 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.72 | 2023-2025 | |
| Axsome Therapeutics, INC. | $251.76 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $187.25 | 2023-2025 | Austedo Xr, Ajovy |
| Medical Device Business Services, INC. | $170.51 | 2024 | Vistaseal |
| E.R. Squibb & Sons, L.L.C. | $145.43 | 2025 | Cobenfy |
| Alkermes, INC. | $144.32 | 2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $135.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $116.13 | 2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $84.06 | 2025 | Rexulti |
| Impel Pharmaceuticals INC. | $40.25 | 2022-2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $37.14 | 2022 | |
| Lundbeck LLC | $36.69 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.71 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $29.49 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.25 | 2025 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.93 | 2023 | Emgality, Reyvow |
| Pfizer INC. | $22.62 | 2023 | |
| Sk Life Science, INC. | $19.74 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Endo USA, INC. | $18.71 | 2024 | Xiaflex |
| Convatec INC. | $13.90 | 2024 | |
| Ethicon US, LLC | $13.29 | 2024 | Dermabond Prineo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rainville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.